ZA200209272B - Aromatic polyurethane polyol. - Google Patents
Aromatic polyurethane polyol. Download PDFInfo
- Publication number
- ZA200209272B ZA200209272B ZA200209272A ZA200209272A ZA200209272B ZA 200209272 B ZA200209272 B ZA 200209272B ZA 200209272 A ZA200209272 A ZA 200209272A ZA 200209272 A ZA200209272 A ZA 200209272A ZA 200209272 B ZA200209272 B ZA 200209272B
- Authority
- ZA
- South Africa
- Prior art keywords
- substance
- composition
- treatment
- pharmaceutically acceptable
- trans
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 title abstract 3
- 229920005862 polyol Polymers 0.000 title abstract 3
- 150000003077 polyols Chemical class 0.000 title abstract 3
- 229920002635 polyurethane Polymers 0.000 title abstract 3
- 239000004814 polyurethane Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 29
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 28
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 23
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 23
- 229960001879 ropinirole Drugs 0.000 claims description 23
- 208000001640 Fibromyalgia Diseases 0.000 claims description 22
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 22
- 229960002802 bromocriptine Drugs 0.000 claims description 22
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 22
- 229960004851 pergolide Drugs 0.000 claims description 22
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 22
- 229960004046 apomorphine Drugs 0.000 claims description 21
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 12
- 229940111121 antirheumatic drug quinolines Drugs 0.000 claims description 10
- 150000003248 quinolines Chemical class 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 9
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 150000002009 diols Chemical class 0.000 abstract 3
- 239000008199 coating composition Substances 0.000 abstract 2
- 239000000758 substrate Substances 0.000 abstract 2
- 239000007795 chemical reaction product Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 125000005442 diisocyanate group Chemical group 0.000 abstract 1
- 239000012948 isocyanate Substances 0.000 abstract 1
- 150000002513 isocyanates Chemical class 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 25
- 239000003814 drug Substances 0.000 description 18
- 239000002552 dosage form Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 238000007911 parenteral administration Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 208000018737 Parkinson disease Diseases 0.000 description 8
- 238000002483 medication Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000007910 chewable tablet Substances 0.000 description 6
- 229940068682 chewable tablet Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 201000001880 Sexual dysfunction Diseases 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 231100000872 sexual dysfunction Toxicity 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000006651 lactation Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- -1 transdermal patch Substances 0.000 description 4
- 206010034010 Parkinsonism Diseases 0.000 description 3
- 102000003946 Prolactin Human genes 0.000 description 3
- 108010057464 Prolactin Proteins 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 229940097325 prolactin Drugs 0.000 description 3
- FTSUPYGMFAPCFZ-ZWNOBZJWSA-N quinpirole Chemical compound C([C@H]1CCCN([C@@H]1C1)CCC)C2=C1C=NN2 FTSUPYGMFAPCFZ-ZWNOBZJWSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- TUFADSGTJUOBEH-ZWNOBZJWSA-N (5aR,9aR)-6-propyl-5a,7,8,9,9a,10-hexahydro-5H-pyrido[2,3-g]quinazolin-2-amine Chemical compound NC1=NC=C2C[C@H]3N(CCC)CCC[C@@H]3CC2=N1 TUFADSGTJUOBEH-ZWNOBZJWSA-N 0.000 description 2
- JXKJBOLPNXKPMG-UHFFFAOYSA-N 1h-pyrazolo[3,4-g]quinoline Chemical compound C1=CN=C2C=C3C=NNC3=CC2=C1 JXKJBOLPNXKPMG-UHFFFAOYSA-N 0.000 description 2
- 241000220479 Acacia Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229940123796 Prolactin inhibitor Drugs 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- UWCVGPLTGZWHGS-ZORIOUSZSA-N pergolide mesylate Chemical compound CS(O)(=O)=O.C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 UWCVGPLTGZWHGS-ZORIOUSZSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229950003275 quinelorane Drugs 0.000 description 2
- 229950001037 quinpirole Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
- MARXMDRWROUXMD-UHFFFAOYSA-N 2-bromoisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(Br)C(=O)C2=C1 MARXMDRWROUXMD-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- FTSUPYGMFAPCFZ-UHFFFAOYSA-N 5-propyl-1,4,4a,6,7,8,8a,9-octahydropyrazolo[3,4-g]quinoline Chemical compound C1C2N(CCC)CCCC2CC2=C1C=NN2 FTSUPYGMFAPCFZ-UHFFFAOYSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 1
- 108090001069 Chymopapain Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- XDXHAEQXIBQUEZ-UHFFFAOYSA-N Ropinirole hydrochloride Chemical compound Cl.CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 XDXHAEQXIBQUEZ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- YDOTUXAWKBPQJW-UHFFFAOYSA-N alpha-Ergocryptinine Natural products C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=CNC3=C1 YDOTUXAWKBPQJW-UHFFFAOYSA-N 0.000 description 1
- YDOTUXAWKBPQJW-NSLWYYNWSA-N alpha-ergocryptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=CNC3=C1 YDOTUXAWKBPQJW-NSLWYYNWSA-N 0.000 description 1
- 229950001817 alpha-ergocryptine Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960003990 apomorphine hydrochloride Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000036649 mental concentration Effects 0.000 description 1
- UWCVGPLTGZWHGS-UHFFFAOYSA-N methanesulfonate;9-(methylsulfanylmethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-7-ium Chemical compound CS(O)(=O)=O.C1=CC(C2CC(CSC)CN(C2C2)CCC)=C3C2=CNC3=C1 UWCVGPLTGZWHGS-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940000596 parlodel Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001511 pergolide mesylate Drugs 0.000 description 1
- 229940088507 permax Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- BTUQCUPQFZHMNS-UHFFFAOYSA-N quinoline;dihydrochloride Chemical compound Cl.Cl.N1=CC=CC2=CC=CC=C21 BTUQCUPQFZHMNS-UHFFFAOYSA-N 0.000 description 1
- 229940113775 requip Drugs 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229960002349 ropinirole hydrochloride Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/77—Polyisocyanates or polyisothiocyanates having heteroatoms in addition to the isocyanate or isothiocyanate nitrogen and oxygen or sulfur
- C08G18/78—Nitrogen
- C08G18/79—Nitrogen characterised by the polyisocyanates used, these having groups formed by oligomerisation of isocyanates or isothiocyanates
- C08G18/791—Nitrogen characterised by the polyisocyanates used, these having groups formed by oligomerisation of isocyanates or isothiocyanates containing isocyanurate groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/30—Low-molecular-weight compounds
- C08G18/32—Polyhydroxy compounds; Polyamines; Hydroxyamines
- C08G18/3203—Polyhydroxy compounds
- C08G18/3206—Polyhydroxy compounds aliphatic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/721—Two or more polyisocyanates not provided for in one single group C08G18/73 - C08G18/80
- C08G18/724—Combination of aromatic polyisocyanates with (cyclo)aliphatic polyisocyanates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/721—Two or more polyisocyanates not provided for in one single group C08G18/73 - C08G18/80
- C08G18/725—Combination of polyisocyanates of C08G18/78 with other polyisocyanates
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D175/00—Coating compositions based on polyureas or polyurethanes; Coating compositions based on derivatives of such polymers
- C09D175/04—Polyurethanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Wood Science & Technology (AREA)
- Polyurethanes Or Polyureas (AREA)
- Paints Or Removers (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57392600A | 2000-05-18 | 2000-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200209272B true ZA200209272B (en) | 2003-07-18 |
Family
ID=24293948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200209272A ZA200209272B (en) | 2000-05-18 | 2002-11-14 | Aromatic polyurethane polyol. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050119439A1 (de) |
| EP (1) | EP1287054B1 (de) |
| JP (1) | JP2003533568A (de) |
| CN (1) | CN100406487C (de) |
| AT (1) | ATE366761T1 (de) |
| AU (2) | AU2001261642B2 (de) |
| BR (1) | BR0110808A (de) |
| DE (1) | DE60129321T2 (de) |
| ES (1) | ES2288512T3 (de) |
| RU (1) | RU2278138C2 (de) |
| WO (1) | WO2001088012A2 (de) |
| ZA (1) | ZA200209272B (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006044653A1 (en) * | 2004-10-14 | 2006-04-27 | Akzo Nobel Coatings International B.V. | Iron carbonyl containing coating composition |
| US20070055026A1 (en) * | 2005-09-07 | 2007-03-08 | Yahkind Alexander L | Melamine polyols and coatings thereof |
| DE102005058891A1 (de) * | 2005-12-09 | 2007-06-14 | Basf Coatings Ag | Flüssige, thermisch härtbare Gemische, Verfahren zu ihrer Herstellung und ihre Verwendung |
| CN102417787A (zh) * | 2011-10-27 | 2012-04-18 | 铜陵市新泰电容电器有限责任公司 | 一种覆盖电容器铝壳涂料及其制备方法 |
| RU2534773C1 (ru) * | 2013-06-07 | 2014-12-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский национальный исследовательский технологический университет" | Полиуретановая композиция для покрытий |
| CN103740256B (zh) * | 2013-12-30 | 2015-10-28 | 江苏标榜装饰新材料股份有限公司 | 适合uv油墨铝塑复合板打印的聚氨酯涂料及其制备方法 |
| US10179830B2 (en) | 2014-06-13 | 2019-01-15 | Covestro Deutschland Ag | Thioallophanate polyisocyanates containing silane groups |
| WO2016205741A1 (en) * | 2015-06-19 | 2016-12-22 | Prc-Desoto International, Inc. | Flexible non-chromate corrosion inhibitive primer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3580881A (en) * | 1970-02-27 | 1971-05-25 | Henry J Lee | Polyurethane coating system |
| JPS50151934A (de) * | 1974-05-31 | 1975-12-06 | ||
| DE2519559C3 (de) * | 1975-05-02 | 1981-10-29 | Messerschmitt-Bölkow-Blohm GmbH, 8000 München | Lackaufbau für metallischen oder nicht metallischen Untergrund, insbesondere für Außenhäute von Flugzeugen |
| US4103050A (en) * | 1976-08-13 | 1978-07-25 | Scm Corporation | Aqueous coil coating primer |
| US4288577A (en) * | 1979-12-14 | 1981-09-08 | E. I. Du Pont De Nemours And Company | Novel urethanediols and polyurethanes therefrom |
| US4542405A (en) * | 1983-06-20 | 1985-09-17 | North American Philips Corporation | Method and apparatus for displaying and reading out an image |
| US4543405A (en) * | 1984-10-01 | 1985-09-24 | Ppg Industries, Inc. | High solids polyurethane polyols and coating compositions thereof |
| US4780340A (en) * | 1986-07-30 | 1988-10-25 | Polyplastics Co., Ltd. | Primer paint or primer surfacer composition |
| US4781986A (en) * | 1987-07-29 | 1988-11-01 | Westinghouse Electric Corp. | Adhesive, bonding method employing same, and product produced thereby |
| US5130405A (en) * | 1989-07-13 | 1992-07-14 | Akzo N.V. | Acid etch resistant coatings |
| US5175227A (en) * | 1989-07-13 | 1992-12-29 | Akzo N.V. | Acid etch resistant coatings containing polyurethane polyols |
| US5155201A (en) * | 1989-07-13 | 1992-10-13 | Akzo N.V. | Polyurethane polyols and high solids coatings therefrom |
| US5384367A (en) * | 1993-04-19 | 1995-01-24 | Ppg Industries, Inc. | Carbamate urea or urethane-functional epoxy acrylic with polyacid |
| US6096835A (en) * | 1997-10-15 | 2000-08-01 | Akzo Nobel N.V. | Film forming binder for coating compositions and coating compositions comprising same |
-
2001
- 2001-05-16 CN CNB018096778A patent/CN100406487C/zh not_active Expired - Fee Related
- 2001-05-16 ES ES01935561T patent/ES2288512T3/es not_active Expired - Lifetime
- 2001-05-16 AT AT01935561T patent/ATE366761T1/de not_active IP Right Cessation
- 2001-05-16 EP EP01935561A patent/EP1287054B1/de not_active Expired - Lifetime
- 2001-05-16 JP JP2001585229A patent/JP2003533568A/ja not_active Withdrawn
- 2001-05-16 WO PCT/US2001/015742 patent/WO2001088012A2/en active IP Right Grant
- 2001-05-16 BR BR0110808-5A patent/BR0110808A/pt not_active Application Discontinuation
- 2001-05-16 DE DE60129321T patent/DE60129321T2/de not_active Expired - Fee Related
- 2001-05-16 RU RU2002133962/04A patent/RU2278138C2/ru not_active IP Right Cessation
- 2001-05-16 AU AU2001261642A patent/AU2001261642B2/en not_active Ceased
- 2001-05-16 AU AU6164201A patent/AU6164201A/xx active Pending
-
2002
- 2002-11-14 ZA ZA200209272A patent/ZA200209272B/en unknown
-
2004
- 2004-12-23 US US11/036,512 patent/US20050119439A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN100406487C (zh) | 2008-07-30 |
| ES2288512T3 (es) | 2008-01-16 |
| JP2003533568A (ja) | 2003-11-11 |
| WO2001088012A2 (en) | 2001-11-22 |
| AU6164201A (en) | 2001-11-26 |
| AU2001261642B2 (en) | 2005-07-28 |
| EP1287054A2 (de) | 2003-03-05 |
| BR0110808A (pt) | 2003-12-30 |
| RU2278138C2 (ru) | 2006-06-20 |
| ATE366761T1 (de) | 2007-08-15 |
| DE60129321D1 (en) | 2007-08-23 |
| US20050119439A1 (en) | 2005-06-02 |
| DE60129321T2 (de) | 2008-03-20 |
| EP1287054B1 (de) | 2007-07-11 |
| WO2001088012A3 (en) | 2002-03-28 |
| CN1437624A (zh) | 2003-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11241429B2 (en) | Method of treating metabolic disorders and depression with dopamine receptor agonists | |
| EP0538422B1 (de) | Neue verwendung von diphenylbutyl-piperazincarboxamiden zur behandlung von störungen im zusammenhang mit der verwendung giftiger stoffen | |
| US9700548B2 (en) | Antihistamines combined with dietary supplements for improved health | |
| EP1634597A1 (de) | Dextromethorphan und Quinidin oder Quinine enthaltende Zusammensetzungen zur Behandlung der Gemütslabilität | |
| KR19990067527A (ko) | 동통의 치료를 위한 에피나스틴의 용도 | |
| TW200418475A (en) | Treatment of pain with combinations of nalbuphine and other kappa-opioid receptor agonists and opioid receptor antagonists | |
| JP2013533297A (ja) | ＧｌｙＴ１化合物と抗精神病薬との組合せ | |
| US11534442B2 (en) | Treatment of adipocytes | |
| US20140271890A1 (en) | Controlled-release pharmaceutical composition | |
| ZA200209272B (en) | Aromatic polyurethane polyol. | |
| US20030212085A1 (en) | Treatment of fibromyalgia and chronic fatigue syndrome | |
| AU2001255223B2 (en) | Treatment of fibromyalgia and chronic fatigue syndrome | |
| AU2001255223A1 (en) | Treatment of fibromyalgia and chronic fatigue syndrome | |
| WO2002083141A1 (en) | Treatment of fibromyalgia and chronic fatigue syndrome | |
| SK284264B6 (sk) | Liečivo na liečenie syndrómu nepokojných nôh | |
| TW201831178A (zh) | 新斯的明(neostigmine)組合及組合物 | |
| US20030078273A1 (en) | Compounds for the treatment of addictive disorders | |
| AU704695B2 (en) | Pyridyl-and pyrimidyl-piperazines in the treatment of substance abuse disorders | |
| EP0440851A1 (de) | Verwendung von Buspiron zur Behandlung von Depressionen | |
| EP1133293A1 (de) | Verwendung von n-substituierten azabicycloalkan-derivaten zur behandlung von erkrankungen des zentralen nervensystems | |
| JP2004026810A (ja) | 鼻炎用組成物 | |
| JP2000212091A (ja) | 消化管機能異常治療剤 | |
| WO2006034788A1 (en) | Combinations of n-(indolecarbonyl-)piperazine derivatives and serotonin reuptake inhibitors | |
| WO2000028984A1 (fr) | Remedes agissant contre un trouble fonctionnel du tractus digestif |